Synergistic impact of exercise and GLP-1 receptor agonist treatment: addressing metabolic syndrome, abdominal obesity, and inflammation

dc.contributor.author	Kuśmierski, Jakub
dc.contributor.author	Kuśmierska, Martyna
dc.date.accessioned	2025-05-26T09:22:12Z
dc.date.available	2025-05-26T09:22:12Z
dc.date.issued	2024-05-17
dc.description.abstract	We are eager to share the findings from a recent article that we had the pleasure of reading, which we believe holds profound significance. Authored by Sandsdal et al. [1], this randomized controlled clinical trial delves into the impact of a combination of exercise and GLP-1 receptor agonist treatment on the severity of metabolic syndrome, abdominal obesity, and inflammation.	en
dc.identifier.citation	Kuśmierski J, Kuśmierska M. Synergistic impact of exercise and GLP-1 receptor agonist treatment: addressing metabolic syndrome, abdominal obesity, and inflammation. Health Prob Civil. 2025; 19(2): 118-119. https://doi.org/10.5114/hpc.2024.139680
dc.identifier.issn	2353-6942
dc.identifier.uri	https://hdl.handle.net/20.500.13044/2228
dc.language.iso	en
dc.publisher	Akademia Bialska im. Jana Pawła II
dc.subject	GLP-1 receptor agonists	en
dc.subject	abdominal obesity	en
dc.subject	metabolic syndrome	en
dc.subject	physical activity	en
dc.subject	inflammation	en
dc.title	Synergistic impact of exercise and GLP-1 receptor agonist treatment: addressing metabolic syndrome, abdominal obesity, and inflammation
dc.type	Article

Aktualna strona 1 - 1 z 1

Aktualna strona 1 - 1 z 1